Case History: Chantix™/Champix™ (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid

被引：21
|
作者：
Coe, Jotham W. [1 ]
Rollema, Hans [1 ]
O'Neill, Brian T. [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44 | 2009年 / 44卷
关键词：
RANDOMIZED CONTROLLED-TRIAL; 10-SUBSTITUTED CYTISINE DERIVATIVES; SUSTAINED-RELEASE BUPROPION; DISCRIMINATIVE STIMULUS; DOSE PHARMACOKINETICS; CHOLINERGIC-RECEPTOR; HEALTHY SMOKERS; BETA-2; SUBUNIT; IN-VIVO; (-)-CYTISINE;
D O I：
10.1016/S0065-7743(09)04404-2
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：71 / +
页数：32
相关论文
共 50 条
  • [41] Association Between Nicotinic Acetylcholine Receptor Single Nucleotide Polymorphisms and Smoking Cessation
    Spruell, Timothy
    Colavita, Guillaume
    Donegan, Tomas
    Egawhary, Marco
    Hurley, Michael
    Aveyard, Paul
    Johnstone, Elaine C.
    Murphy, Michael F. G.
    Munafo, Marcus R.
    NICOTINE & TOBACCO RESEARCH, 2012, 14 (08) : 993 - 997
  • [42] Varenicline, a partial agonist at α4β2 nicotinic acetylcholine receptors selectively decreases ethanol consumption and seeking
    Steensland, Pia
    Simms, Jeff
    Holgate, Joan
    Richards, Jemma
    Bartlett, Selena
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (08) : SMA39 - SMA40
  • [43] Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation
    Tutka, Piotr
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (10) : 1473 - 1485
  • [44] Partial nicotinic acetylcholine (α4β2) agonists as promising new medications for smoking cessation
    Singh, J.
    Budhiraja, Salil
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 (05) : 191 - 196
  • [45] Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments
    Lambert, C. S.
    Philpot, R. M.
    Engberg, M. E.
    Johns, B. E.
    Wecker, L.
    BEHAVIOURAL BRAIN RESEARCH, 2015, 291 : 342 - 350
  • [46] Effects of the Nicotinic Partial Agonist Varenicline on Smoking Lapse Behavior in Smokers With and Without Schizophrenia: Preliminary Studies
    Sharif-Razi, Maryam
    Kozak, Karolina
    Coles, Alexandria
    Morozova, Marya
    Zochniak, Michelle
    Gaudette, Erin
    Wing, Victoria
    Barr, Mera
    Mckee, Sherry
    George, Tony
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S287 - S288
  • [47] The Efficacy and Safety of Varenicline, a Selective Alpha4beta2 Nicotinic Receptor Partial Agonist, for Smoking Cessation in Patients Hospitalized With Acute Coronary Syndrome: A Randomized Controlled Trial
    Eisenberg, Mark J.
    Windle, Sarah B.
    Roy, Nathalie
    Old, Wayne
    Grondin, Franois
    Bata, Iqbal
    Iskander, Ayman
    lauzon, Claude
    Srivastava, Nalin
    Clarke, Adam
    Cassavar, Daniel
    Dion, Danielle
    Haught, Herbert
    Mehta, Shamir
    Baril, Jean-Francois
    Lambert, Charles
    Madan, Mina
    Abramson, Beth L.
    Dehghani, Payam
    CIRCULATION, 2015, 132 (23) : 2269 - 2270
  • [48] Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers
    Faessel, Helene M.
    Gibbs, Megan A.
    Clark, David J.
    Rohrbacher, Kevin
    Stolar, Marilyn
    Burstein, Aaron H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (12): : 1439 - 1448
  • [49] Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment A Randomized Trial
    Brody, Arthur L.
    Mukhin, Alexey G.
    Mamoun, Michael S.
    Trinh Luu
    Neary, Meaghan
    Liang, Lidia
    Shieh, Jennifer
    Sugar, Catherine A.
    Rose, Jed E.
    Mandelkern, Mark A.
    JAMA PSYCHIATRY, 2014, 71 (07) : 797 - 805
  • [50] Smoking Cessation and Variations in Nicotinic Acetylcholine Receptor Subunits α-5, α-3, and β-4 Genes
    Breitling, Lutz Philipp
    Dahmen, Norbert
    Mittelstrass, Kirstin
    Illig, Thomas
    Rujescu, Dan
    Raum, Elke
    Winterer, Georg
    Brenner, Hermann
    BIOLOGICAL PSYCHIATRY, 2009, 65 (08) : 691 - 695
12345